Clinically, bevacizumab, a recombinant humanized monoclonal antibody that neutralizes vascular endothelial growth factor-A (VEGF-A, or VEGF), is used in the first-line treatment of metastatic colorectal cancer (CRC) and produced significant survival improvement [1]. This evidence concerns the gene VEGFA and metastatic colorectal cancer.